Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Geiser

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Annals of the American Thoracic Society|May 20, 2021
Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Crossover TrialSabina A Guler, Christian Clarenbach, Martin Brutsche, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 12, 2002
Activity of pulmonary edema fluid interleukin-8 bound to alpha(2)-macroglobulin in patients with acute lung injuryAnna K Kurdowska, Thomas K Geiser, Susanne M Alden, et al.
Biofabrication|December 17, 2025
Microengineered alveolar array lung-on-chip with hydrogel membrane and simulated breathing mechanics for anti-fibrotic testingTobias Weber, Pauline Zamprogno, Sabine Schneider, et al.
Respiratory Research|June 8, 2022
Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational studySabina A Guler, Carlos Machahua, Thomas K Geiser, et al.
BMJ Open Respiratory Research|January 16, 2021
Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohortsCarlos Machahua, Sabina A Guler, Michael P Horn, et al.
Respiratory Research|January 17, 2020
Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls [corrected]Kristina Krempaska, Sandra Barnowski, Jacopo Gavini, et al.
BMC Infectious Diseases|October 3, 2023
Circulating calprotectin levels four months after severe and non-severe COVID-19N Abu Hussein, C Machahua, S C Ruchti, et al.
Respiratory Research|January 30, 2020
Correction to: Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controlsKristina Krempaska, Sandra Barnowski, Jacopo Gavini, et al.
BMJ Open Respiratory Research|April 23, 2022
Frailty assessment for COVID-19 follow-up: a prospective cohort studyIlena Müller, Marco Mancinetti, Anja Renner, et al.
The European Respiratory Journal|January 9, 2021
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung studySabina A Guler, Lukas Ebner, Catherine Aubry-Beigelman, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Annals of the American Thoracic Society|May 20, 2021
Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Crossover TrialSabina A Guler, Christian Clarenbach, Martin Brutsche, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 12, 2002
Activity of pulmonary edema fluid interleukin-8 bound to alpha(2)-macroglobulin in patients with acute lung injuryAnna K Kurdowska, Thomas K Geiser, Susanne M Alden, et al.
Biofabrication|December 17, 2025
Microengineered alveolar array lung-on-chip with hydrogel membrane and simulated breathing mechanics for anti-fibrotic testingTobias Weber, Pauline Zamprogno, Sabine Schneider, et al.
Respiratory Research|June 8, 2022
Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational studySabina A Guler, Carlos Machahua, Thomas K Geiser, et al.
BMJ Open Respiratory Research|January 16, 2021
Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohortsCarlos Machahua, Sabina A Guler, Michael P Horn, et al.
Respiratory Research|January 17, 2020
Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls [corrected]Kristina Krempaska, Sandra Barnowski, Jacopo Gavini, et al.
BMC Infectious Diseases|October 3, 2023
Circulating calprotectin levels four months after severe and non-severe COVID-19N Abu Hussein, C Machahua, S C Ruchti, et al.
Respiratory Research|January 30, 2020
Correction to: Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controlsKristina Krempaska, Sandra Barnowski, Jacopo Gavini, et al.
BMJ Open Respiratory Research|April 23, 2022
Frailty assessment for COVID-19 follow-up: a prospective cohort studyIlena Müller, Marco Mancinetti, Anja Renner, et al.
The European Respiratory Journal|January 9, 2021
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung studySabina A Guler, Lukas Ebner, Catherine Aubry-Beigelman, et al.
Pageof 3